204 related articles for article (PubMed ID: 9111826)
1. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.
Meffert H; Bräutigam M; Färber L; Weidinger G
Acta Derm Venereol; 1997 Mar; 77(2):137-41. PubMed ID: 9111826
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
Reitamo S; Spuls P; Sassolas B; Lahfa M; Claudy A; Griffiths CE;
Br J Dermatol; 2001 Sep; 145(3):438-45. PubMed ID: 11531834
[TBL] [Abstract][Full Text] [Related]
3. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.
Ito T; Furukawa F; Iwatsuki K; Matsue H; Shimada S; Takigawa M; Tokura Y
J Dermatol; 2014 May; 41(5):377-81. PubMed ID: 24628433
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis.
Shintani Y; Kaneko N; Furuhashi T; Saito C; Morita A
J Dermatol; 2011 Oct; 38(10):966-72. PubMed ID: 21545506
[TBL] [Abstract][Full Text] [Related]
5. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
Ieiri I; Nakayama J; Murakami H; Hori Y; Higuchi S
Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
[TBL] [Abstract][Full Text] [Related]
7. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
Gottlieb AB; Griffiths CE; Ho VC; Lahfa M; Mrowietz U; Murrell DF; Ortonne JP; Todd G; Cherill R; Marks I; Emady-Azar S; Paul CF;
Br J Dermatol; 2005 Jun; 152(6):1219-27. PubMed ID: 15948985
[TBL] [Abstract][Full Text] [Related]
8. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
9. Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study.
Colombo D; Cassano N; Altomare G; Giannetti A; Vena GA
Int J Immunopathol Pharmacol; 2010; 23(4):1143-52. PubMed ID: 21244763
[TBL] [Abstract][Full Text] [Related]
10. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis.
Ohtsuki M; Nakagawa H; Sugai J; Ozawa A; Ohkido M; Nakayama J; Hanada J; Morimoto Y; Jimbow K; Horikoshi T; Kitahara H; Tamaki K; Urabe K; Hori Y
J Dermatol; 2003 Apr; 30(4):290-8. PubMed ID: 12707465
[TBL] [Abstract][Full Text] [Related]
11. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
Yoon HS; Youn JI
J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632
[TBL] [Abstract][Full Text] [Related]
12. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
13. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
Salek MS; Finlay AY; Lewis JJ; Sumner MI
Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
[TBL] [Abstract][Full Text] [Related]
14. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis.
Erkko P; Granlund H; Remitz A; Rosen K; Mobacken H; Lindelöf B; Reitamo S
Br J Dermatol; 1998 Dec; 139(6):997-1004. PubMed ID: 9990362
[TBL] [Abstract][Full Text] [Related]
15. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
Chaidemenos GC; Mourellou O; Avgoustinaki N; Papakonstantinou M; Karakatsanis G; Katsambas A
J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
Hashizume H; Ito T; Yagi H; Takigawa M; Kageyama H; Furukawa F; Hata M; Shirahama S; Tanaka M; Higashishiba T; Machida H; Tsushima T; Matsushita K
J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.
Berth-Jones J; Henderson CA; Munro CS; Rogers S; Chalmers RJ; Boffa MJ; Norris PG; Friedmann PS; Graham-Brown RA; Dowd PM; Marks R; Sumner MJ
Br J Dermatol; 1997 Apr; 136(4):527-30. PubMed ID: 9155952
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment.
Chow C; Simpson MJ; Luger TA; Chubb H; Ellis CN
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1406-14. PubMed ID: 25917315
[TBL] [Abstract][Full Text] [Related]
19. Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
Dermatology; 1993; 187 Suppl 1():30-7. PubMed ID: 8369577
[TBL] [Abstract][Full Text] [Related]
20. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
Ho VC; Griffiths CE; Albrecht G; Vanaclocha F; León-Dorantes G; Atakan N; Reitamo S; Ohannesson A; Mørk NJ; Clarke P; Pfister P; Paul C
Br J Dermatol; 1999 Aug; 141(2):283-91. PubMed ID: 10468801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
